{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,4]],"date-time":"2026-09-04T14:24:17Z","timestamp":1788531857861,"version":"build-2803163510"},"reference-count":85,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,9,4]],"date-time":"2026-09-04T00:00:00Z","timestamp":1788480000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Oncol."],"abstract":"<jats:p>Glioblastoma remains the most aggressive primary malignant brain tumor in adults. Disease progression is driven by multiple biological mechanisms, including glioma stem cell persistence, intratumoral heterogeneity, hypoxia-associated treatment resistance, enhanced DNA damage repair, immune evasion, and dynamic interactions within the tumor microenvironment. These factors contribute to therapeutic failure and highlight the need for novel treatment strategies and biomarker-driven approaches guiding patient selection and response assessment. Alpha particle therapy is a promising modality due to it\u2019s high linear energy transfer (LET), short tissue range, and potent relative biological effectiveness (RBE), inducing complex DNA damage that is difficult to repair while limiting radiation exposure to surrounding normal tissue. Among emerging platforms, Diffusing Alpha-emitters Radiation Therapy (Alpha DaRT) enables sustained intratumoral delivery of alpha-emitting radionuclides, while targeted alpha therapies employ tumor-specific radiopharmaceuticals to selectively deliver highly cytotoxic radiation to malignant cells. Beyond direct tumor cell killing, accumulating evidence suggests alpha particle therapy targets several biological pathways implicated in glioblastoma progression, including DNA damage response signaling, glioma stem cell survival, hypoxia-driven adaptation, and immune suppression. These mechanisms generated growing interest in the identification of predictive and pharmacodynamic biomarkers capable of guiding treatment selection and monitoring therapeutic response. Candidate biomarkers include DNA repair-associated proteins, stemness-related markers, molecular alterations such as MGMT and IDH status, liquid biopsy analytes, and advanced imaging biomarkers. In this review, we summarize current alpha-emitting therapeutic strategies for glioblastoma, with particular emphasis on Alpha DaRT, and discuss emerging biological mechanisms of response, biomarkers associated with tumor progression and therapeutic sensitivity, and opportunities for biomarker-guided clinical implementation.<\/jats:p>","DOI":"10.3389\/fonc.2026.1940181","type":"journal-article","created":{"date-parts":[[2026,9,4]],"date-time":"2026-09-04T13:51:24Z","timestamp":1788529884000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Alpha particle therapy in glioblastoma: emerging biomarkers, mechanisms of response, and translational opportunities"],"prefix":"10.3389","volume":"16","author":[{"given":"Tugce","family":"Kutuk","sequence":"first","affiliation":[{"name":"Department of Radiation Oncology, The Ohio State University Wexner Medical Center","place":["Columbus, OH, United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ece","family":"Atak","sequence":"additional","affiliation":[{"name":"Department of Radiation Oncology, Basaksehir Cam and Sakura City Hospital","place":["Istanbul, T\u00fcrkiye"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marshall","family":"Harrell","sequence":"additional","affiliation":[{"name":"Department of Radiation Oncology, The Ohio State University Wexner Medical Center","place":["Columbus, OH, United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Raju","family":"Raval","sequence":"additional","affiliation":[{"name":"Department of Radiation Oncology, The Ohio State University Wexner Medical Center","place":["Columbus, OH, United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sasha","family":"Beyer","sequence":"additional","affiliation":[{"name":"Department of Radiation Oncology, The Ohio State University Wexner Medical Center","place":["Columbus, OH, United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Simeng","family":"Zhu","sequence":"additional","affiliation":[{"name":"Department of Radiation Oncology, The Ohio State University Wexner Medical Center","place":["Columbus, OH, United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John","family":"Grecula","sequence":"additional","affiliation":[{"name":"Department of Radiation Oncology, The Ohio State University Wexner Medical Center","place":["Columbus, OH, United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fatemeh","family":"Fekrmandi","sequence":"additional","affiliation":[{"name":"Department of Radiation Oncology, The Ohio State University Wexner Medical Center","place":["Columbus, OH, United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sean S.","family":"Mahase","sequence":"additional","affiliation":[{"name":"Department of Radiation Oncology, The Ohio State University Wexner Medical Center","place":["Columbus, OH, United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Khaled","family":"Dibs","sequence":"additional","affiliation":[{"name":"Department of Radiation Oncology, The Ohio State University Wexner Medical Center","place":["Columbus, OH, United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel","family":"Trifiletti","sequence":"additional","affiliation":[{"name":"Department of Radiation Oncology, Mayo Clinic Florida","place":["Jacksonville, FL, United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Raj","family":"Singh","sequence":"additional","affiliation":[{"name":"Department of Radiation Oncology, Lynn Cancer Institute, Baptist Health South Florida","place":["Boca Raton, FL, United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James Bradley","family":"Elder","sequence":"additional","affiliation":[{"name":"Department of Neurological Surgery, The Ohio State University Wexner Medical Center","place":["Columbus, OH, United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kyle","family":"Wu","sequence":"additional","affiliation":[{"name":"Department of Neurological Surgery, The Ohio State University Wexner Medical Center","place":["Columbus, OH, United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pierre","family":"Giglio","sequence":"additional","affiliation":[{"name":"Division of Neuro-Oncology, Department of Neurology, The Ohio State University Wexner Medical Center","place":["Columbus, OH, United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dukagjin M.","family":"Blakaj","sequence":"additional","affiliation":[{"name":"Department of Radiation Oncology, The Ohio State University Wexner Medical Center","place":["Columbus, OH, United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arnab","family":"Chakravarti","sequence":"additional","affiliation":[{"name":"Department of Radiation Oncology, The Ohio State University Wexner Medical Center","place":["Columbus, OH, United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joshua","family":"Palmer","sequence":"additional","affiliation":[{"name":"Department of Radiation Oncology, The Ohio State University Wexner Medical Center","place":["Columbus, OH, United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,9,4]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"iv1","DOI":"10.1093\/neuonc\/noaf194","article-title":"CBTRUS statistical report: Primary brain and other central nervous system tumors diagnosed in the United States in 2018-2022","volume":"27","author":"Price","year":"2025","journal-title":"Neuro Oncol"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1201\/9781003416197-1","article-title":"Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma","volume":"352","author":"Stupp","year":"2005","journal-title":"N Engl J Med"},{"key":"B3","article-title":"Progression-free survival 2 as a potential surrogate for overall survival in glioblastoma: Insights from a Spanish multicentric cohort","volume":"15","author":"Yaringa\u00f1o","year":"2026","journal-title":"Cancer Med-Us"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1016\/s1470-2045(09)70025-7","article-title":"Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial","volume":"10","author":"Stupp","year":"2009","journal-title":"Lancet Oncol"},{"key":"B5","doi-asserted-by":"publisher","first-page":"64","DOI":"10.21037\/cco-23-82","article-title":"Tumor treating fields: Narrative review of a promising treatment modality for cancer","volume":"12","author":"Kutuk","year":"2023","journal-title":"Chin Clin Oncol"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijrobp.2009.09.018","article-title":"Patterns and timing of recurrence after temozolomide-based chemoradiation for glioblastoma","volume":"78","author":"Milano","year":"2010","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.3390\/cancers15133458","article-title":"Emerging role of glioma stem cells in mechanisms of therapy resistance","volume":"15","author":"Eckerdt","year":"2023","journal-title":"Cancers (Basel)"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijrobp.2026.04.013","article-title":"Mechanisms, microenvironments, and models: Understanding therapeutic resistance in glioblastoma","author":"Wisdom","year":"2026","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdx169","article-title":"Intratumoral heterogeneity: Pathways to treatment resistance and relapse in human glioblastoma","volume":"28","author":"Qazi","year":"2017","journal-title":"Ann Oncol"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1111\/imm.70087","article-title":"The immunosuppressive microenvironment of glioblastoma: Mechanisms, clinical challenges and future directions","volume":"177","author":"Pang","year":"2026","journal-title":"Immunology"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1016\/s1470-2045(18)30675-2","article-title":"Regorafenib compared with lomustine in patients with relapsed glioblastoma (REGOMA): A multicentre, open-label, randomised, controlled, phase 2 trial","volume":"20","author":"Lombardi","year":"2019","journal-title":"Lancet Oncol"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1093\/neuonc\/noaf072","article-title":"Therapy for diffuse astrocytic and oligodendroglial tumors in adults: ASCO-SNO guideline rapid recommendation update","volume":"43","author":"Blakeley","year":"2025","journal-title":"J Clin Oncol"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.3390\/cancers14122946","article-title":"Pulsed-reduced dose rate (PRDR) radiotherapy for recurrent primary central nervous system Malignancies: Dosimetric and clinical results","volume":"14","author":"Kutuk","year":"2022","journal-title":"Cancers (Basel)"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1001\/jamaoncol.2018.4044","article-title":"Targeted alpha therapy, an emerging class of cancer agents: A review","volume":"4","author":"Targeted Alpha Therapy Working","year":"2018","journal-title":"JAMA Oncol"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1080\/09553002.2025.2590742","article-title":"Differential roles of DNA double strand break repair pathways in response to X-ray, proton, and alpha-particle irradiation","volume":"102","author":"van de Kamp","year":"2026","journal-title":"Int J Radiat Biol"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0064730","article-title":"Alpha-particle emitting 213Bi-anti-EGFR immunoconjugates eradicate tumor cells independent of oxygenation","volume":"8","author":"Wulbrand","year":"2013","journal-title":"PloS One"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.7150\/thno.106081","article-title":"Current landscape and future directions of targeted-alpha-therapy for glioblastoma treatment","volume":"15","author":"Roncali","year":"2025","journal-title":"Theranostics"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.3892\/ijo.2026.5907","article-title":"Radiotherapy resistance in glioblastoma: mechanistic insights and novel therapeutic approaches (review)","volume":"69","author":"Zhang","year":"2026","journal-title":"Int J Oncol"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.3389\/fmed.2022.1085245","article-title":"Targeted alpha therapy for glioblastoma","volume":"9","author":"Kunikowska","year":"2022","journal-title":"Front Med (Lausanne)"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1016\/s1470-2045(24)00075-5","article-title":"Radiotherapy, immunity, and immune checkpoint inhibitors","volume":"25","author":"Lynch","year":"2024","journal-title":"Lancet Oncol"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2022.888100","article-title":"Diffusing alpha-emitters radiation therapy in combination with temozolomide or bevacizumab in human glioblastoma multiforme xenografts","volume":"12","author":"Nishri","year":"2022","journal-title":"Front Oncol"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1007\/s11060-024-04919-5","article-title":"Stereotactic implantation of diffusing alpha-emitters radiation therapy sources in the swine brain: A potential new focal therapy for brain tumors","volume":"172","author":"Shoshan","year":"2025","journal-title":"J Neuro-Oncol"},{"key":"B23","doi-asserted-by":"crossref","DOI":"10.1097\/RLU.0000000000004608","article-title":"Locoregional treatment of glioblastoma with targeted alpha therapy: [ 213 Bi]Bi-DOTA-Substance P versus [ 225 Ac]Ac-DOTA-Substance P-analysis of influence parameters","volume":"48","author":"Krolicki","year":"2023","journal-title":"Clin Nucl Med"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1016\/j.nucmedbio.2025.109044","article-title":"Radiobiological effect of alpha particles. The scientific basis of targeted alpha-particle therapy","author":"Cruz-Nova","year":"2025","journal-title":"Nucl Med Biol"},{"key":"B25","doi-asserted-by":"publisher","first-page":"015015","DOI":"10.1088\/1361-6560\/ab5b73","article-title":"Diffusing alpha-emitters radiation therapy: Approximate modeling of the macroscopic alpha particle dose of a point source","volume":"65","author":"Arazi","year":"2020","journal-title":"Phys Med Biol"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1002\/mp.17020","article-title":"First measurements of radon-220 diffusion in mice tumors, towards treatment planning in diffusing alpha-emitters radiation therapy","volume":"51","author":"Heger","year":"2024","journal-title":"Med Phys"},{"key":"B27","doi-asserted-by":"crossref","DOI":"10.1002\/mp.70052","article-title":"Diffusing alpha-emitters radiation therapy: In vivo measurements of effective diffusion and clearance rates across multiple tumor types","volume":"52","author":"Dumancic","year":"2025","journal-title":"Med Phys"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.3390\/cancers16132312","article-title":"Extended follow-up outcomes from pooled prospective studies evaluating efficacy of interstitial alpha radionuclide treatment for skin and head and neck cancers","volume":"16","author":"Popovtzer","year":"2024","journal-title":"Cancers (Basel)"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijrobp.2019.10.048","article-title":"Initial safety and tumor control results from a \"first-in-human\" multicenter prospective trial evaluating a novel alpha-emitting radionuclide for the treatment of locally advanced recurrent squamous cell carcinomas of the skin and head and neck","volume":"106","author":"Popovtzer","year":"2020","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.1200\/jco.2026.44.2_suppl.721","article-title":"Feasibility, safety and efficacy of endoscopic ultrasound-guided alpha radiotherapy for advanced pancreatic cancer: A pilot study","volume":"44","author":"Miller","year":"2026","journal-title":"J Clin Oncol"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijrobp.2022.08.043","article-title":"Diffusing alpha-emitters radiation therapy promotes a proimmunogenic tumor microenvironment and synergizes with programmed cell death protein 1 blockade","volume":"115","author":"Mare","year":"2023","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.1007\/s00262-019-02418-5","article-title":"Combining alpha radiation-based brachytherapy with immunomodulators promotes complete tumor regression in mice via tumor-specific long-term immune response","volume":"68","author":"Domankevich","year":"2019","journal-title":"Cancer Immunol Immunother"},{"key":"B33","doi-asserted-by":"crossref","DOI":"10.1155\/2022\/6291504","article-title":"The neurokinin-1 receptor is essential for the viability of human glioma cells: A possible target for treating glioblastoma","volume":"2022","author":"Munoz","year":"2022","journal-title":"BioMed Res Int"},{"key":"B34","doi-asserted-by":"crossref","DOI":"10.1053\/j.semnuclmed.2019.11.004","article-title":"(225)Ac- and (213)Bi-substance P analogues for glioma therapy","volume":"50","author":"Krolicki","year":"2020","journal-title":"Semin Nucl Med"},{"key":"B35","doi-asserted-by":"crossref","DOI":"10.1007\/s00259-021-05350-y","article-title":"Dose escalation study of targeted alpha therapy with [(225)Ac]Ac-DOTA-substance P in recurrence glioblastoma - safety and efficacy","volume":"48","author":"Krolicki","year":"2021","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"B36","doi-asserted-by":"crossref","DOI":"10.1007\/s00259-018-4225-7","article-title":"Safety and efficacy of targeted alpha therapy with (213)Bi-DOTA-substance P in recurrent glioblastoma","volume":"46","author":"Krolicki","year":"2019","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"B37","doi-asserted-by":"publisher","DOI":"10.1007\/s00259-010-1385-5","article-title":"Targeted alpha-radionuclide therapy of functionally critically located gliomas with 213Bi-DOTA-[Thi8,Met(O2)11]-substance P: A pilot trial","volume":"37","author":"Cordier","year":"2010","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"B38","doi-asserted-by":"publisher","DOI":"10.1007\/s00259-018-4015-2","article-title":"Prolonged survival in secondary glioblastoma following local injection of targeted alpha therapy with (213)Bi-substance P analogue","volume":"45","author":"Krolicki","year":"2018","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"B39","doi-asserted-by":"publisher","DOI":"10.1007\/s00259-025-07332-w","article-title":"Low-dose temozolomide selectively increases glioblastoma's vascular permeability, tumor microenvironment penetration and the killing potential of systemic actinium-225 alpha-particle dendrimer-radioconjugates improving treatment efficacy","volume":"52","author":"Nair","year":"2025","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"B40","doi-asserted-by":"publisher","DOI":"10.1111\/cbdd.13199","article-title":"In vitro evaluation of 225Ac-DOTA-substance P for targeted alpha therapy of glioblastoma multiforme","volume":"92","author":"Majkowska-Pilip","year":"2018","journal-title":"Chem Biol Drug Des"},{"key":"B41","doi-asserted-by":"publisher","DOI":"10.2967\/jnumed.107.046938","article-title":"Clinical experience with alpha-particle emitting 211At: treatment of recurrent brain tumor patients with 211At-labeled chimeric antitenascin monoclonal antibody 81C6","volume":"49","author":"Zalutsky","year":"2008","journal-title":"J Nucl Med"},{"key":"B42","doi-asserted-by":"publisher","DOI":"10.2967\/jnumed.116.173559","article-title":"Remodeling the vascular microenvironment of glioblastoma with alpha-particles","volume":"57","author":"Behling","year":"2016","journal-title":"J Nucl Med"},{"key":"B43","doi-asserted-by":"publisher","DOI":"10.2967\/jnumed.115.171371","article-title":"Vascular targeted radioimmunotherapy for the treatment of glioblastoma","volume":"57","author":"Behling","year":"2016","journal-title":"J Nucl Med"},{"key":"B44","doi-asserted-by":"publisher","DOI":"10.18632\/oncotarget.17792","article-title":"IL13RA2 targeted alpha particle therapy against glioblastomas","volume":"8","author":"Sattiraju","year":"2017","journal-title":"Oncotarget"},{"key":"B45","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.can-07-1493","article-title":"Expression of interleukin-13 receptor alpha2 in glioblastoma multiforme: implications for targeted therapies","volume":"67","author":"Jarboe","year":"2007","journal-title":"Cancer Res"},{"key":"B46","doi-asserted-by":"publisher","first-page":"18248","DOI":"10.1038\/s41598-025-03356-2","article-title":"Locoregional radionuclide therapy of glioblastoma with [(211)At]At-PDA-FAPI","volume":"15","author":"Ma","year":"2025","journal-title":"Sci Rep"},{"key":"B47","doi-asserted-by":"publisher","DOI":"10.1016\/j.bmc.2021.116600","article-title":"In vitro and in vivo evaluation of (211)At-labeled fibroblast activation protein inhibitor for glioma treatment","volume":"55","author":"Ma","year":"2022","journal-title":"Bioorg Med Chem"},{"key":"B48","doi-asserted-by":"publisher","DOI":"10.1016\/j.nucmedbio.2025.109572","article-title":"Evaluation of an (211)At-labeled RGD peptide in an orthotopic glioblastoma model by targeted alpha therapy","author":"Echigo","year":"2025","journal-title":"Nucl Med Biol"},{"key":"B49","doi-asserted-by":"publisher","DOI":"10.1016\/j.ebiom.2024.105202","article-title":"Brain intratumoural astatine-211 radiotherapy targeting syndecan-1 leads to durable glioblastoma remission and immune memory in female mice","volume":"105","author":"Roncali","year":"2024","journal-title":"EBioMedicine"},{"key":"B50","doi-asserted-by":"publisher","DOI":"10.3390\/genes11010099","article-title":"Clustered DNA double-strand breaks: Biological effects and relevance to cancer radiotherapy","volume":"11","author":"Nickoloff","year":"2020","journal-title":"Genes (Basel)"},{"key":"B51","doi-asserted-by":"publisher","DOI":"10.1111\/imr.13409","article-title":"A comprehensive review of sensors of radiation-induced damage, radiation-induced proximal events, and cell death","volume":"329","author":"Saini","year":"2025","journal-title":"Immunol Rev"},{"key":"B52","doi-asserted-by":"publisher","DOI":"10.1667\/rr2803.1","article-title":"In vitro evaluation of combined temozolomide and radiotherapy using X rays and high-linear energy transfer radiation for glioblastoma","volume":"177","author":"Barazzuol","year":"2012","journal-title":"Radiat Res"},{"key":"B53","doi-asserted-by":"publisher","first-page":"195","DOI":"10.1667\/rr2071.1","article-title":"Participation of DNA-PKcs in DSB repair after exposure to high- and low-LET radiation","volume":"174","author":"Anderson","year":"2010","journal-title":"Radiat Res"},{"key":"B54","doi-asserted-by":"publisher","DOI":"10.3390\/cancers13215358","article-title":"Expression levels of RAD51 inversely correlate with survival of glioblastoma patients","volume":"13","author":"Morrison","year":"2021","journal-title":"Cancers (Basel)"},{"key":"B55","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.can-14-3790","article-title":"Selective inhibition of parallel DNA damage response pathways optimizes radiosensitization of glioblastoma stem-like cells","volume":"75","author":"Ahmed","year":"2015","journal-title":"Cancer Res"},{"key":"B56","doi-asserted-by":"publisher","DOI":"10.1016\/j.stemcr.2016.12.005","article-title":"RAD51 is a selective DNA repair target to radiosensitize glioma stem cells","volume":"8","author":"King","year":"2017","journal-title":"Stem Cell Rep"},{"key":"B57","doi-asserted-by":"publisher","DOI":"10.1155\/2016\/5728438","article-title":"Glioma stem cells and their microenvironments: Providers of challenging therapeutic targets","volume":"2016","author":"Codrici","year":"2016","journal-title":"Stem Cells Int"},{"key":"B58","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1093\/jrr\/rrt095","article-title":"High linear-energy-transfer radiation can overcome radioresistance of glioma stem-like cells to low linear-energy-transfer radiation","volume":"55","author":"Hirota","year":"2014","journal-title":"J Radiat Res"},{"key":"B59","doi-asserted-by":"publisher","DOI":"10.1016\/j.neo.2014.04.002","article-title":"Antitumor immunity induced after alpha irradiation","volume":"16","author":"Gorin","year":"2014","journal-title":"Neoplasia"},{"key":"B60","doi-asserted-by":"publisher","first-page":"790","DOI":"10.1016\/j.ijrobp.2021.10.013","article-title":"Targeted alpha particle therapy remodels the tumor microenvironment and improves efficacy of immunotherapy","volume":"112","author":"Perrin","year":"2022","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"B61","doi-asserted-by":"publisher","DOI":"10.2967\/jnumed.124.268857","article-title":"MHC-I-driven antitumor immunity counterbalances low absorbed doses of radiopharmaceutical therapy","volume":"66","author":"Constanzo","year":"2025","journal-title":"J Nucl Med"},{"key":"B62","article-title":"Immunomodulatory effects of targeted radionuclide therapy","volume":"378","author":"Constanzo","year":"2023","journal-title":"Int Rev Cell Mol Biol"},{"key":"B63","doi-asserted-by":"publisher","DOI":"10.1158\/2326-6066.cir-24-1191","article-title":"The effects of clinically relevant radionuclides on the activation of an IFN1 response correlate with radionuclide half-life and linear energy transfer and influence radiopharmaceutical antitumor efficacy","volume":"13","author":"Kerr","year":"2025","journal-title":"Cancer Immunol Res"},{"key":"B64","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2025.1563387","article-title":"Immunomodulatory effects of alpha vs beta radiopharmaceutical therapy in murine prostate cancer","volume":"16","author":"Ferreira","year":"2025","journal-title":"Front Immunol"},{"key":"B65","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2026.1734404","article-title":"Progress in molecular markers associated with radiotherapy efficacy in glioma","volume":"16","author":"Gao","year":"2026","journal-title":"Front Oncol"},{"key":"B66","doi-asserted-by":"publisher","DOI":"10.1038\/nature05236","article-title":"Glioma stem cells promote radioresistance by preferential activation of the DNA damage response","volume":"444","author":"Bao","year":"2006","journal-title":"Nature"},{"key":"B67","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijrobp.2026.03.004","article-title":"Constraints, cumulative doses and toxicity outcomes in glioma reirradiation: a systematic review and radiobiological comparison from the reirradiation collaborative group (ReCog)","author":"Slevin","year":"2026","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"B68","doi-asserted-by":"publisher","DOI":"10.1016\/s1470-2045(26)00235-4","article-title":"Dose escalation with intraoperative radiotherapy in newly diagnosed glioblastoma (INTRAGO-II): an open-label, multicentre, randomised, controlled, phase 3 trial","volume":"27","author":"Giordano","year":"2026","journal-title":"Lancet Oncol"},{"key":"B69","article-title":"Prognostic implications of the DNA damage response pathway in glioblastoma","volume":"26","author":"Seol","year":"2011","journal-title":"Oncol Rep"},{"key":"B70","doi-asserted-by":"publisher","DOI":"10.1016\/j.molonc.2014.06.012","article-title":"Increased sensitivity to ionizing radiation by targeting the homologous recombination pathway in glioma initiating cells","volume":"8","author":"Lim","year":"2014","journal-title":"Mol Oncol"},{"key":"B71","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.adj5962","article-title":"Aberrant ATM signaling and homology-directed DNA repair as a vulnerability of p53-mutant GBM to AZD1390-mediated radiosensitization","volume":"16","author":"Chen","year":"2024","journal-title":"Sci Transl Med"},{"key":"B72","doi-asserted-by":"publisher","DOI":"10.1111\/jnc.12802","article-title":"Primary glioblastoma cultures: can profiling of stem cell markers predict radiotherapy sensitivity","volume":"131","author":"Lemke","year":"2014","journal-title":"J Neurochem"},{"key":"B73","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0172791","article-title":"Expression of CD133 and CD44 in glioblastoma stem cells correlates with cell proliferation, phenotype stability and intra-tumor heterogeneity","volume":"12","author":"Brown","year":"2017","journal-title":"PloS One"},{"key":"B74","doi-asserted-by":"publisher","DOI":"10.3390\/cancers13153676","article-title":"Targeted alpha-particle radiotherapy and immune checkpoint inhibitors induces cooperative inhibition on tumor growth of Malignant melanoma","volume":"13","author":"Li","year":"2021","journal-title":"Cancers (Basel)"},{"key":"B75","doi-asserted-by":"publisher","DOI":"10.1016\/j.immuni.2014.10.019","article-title":"STING-dependent cytosolic DNA sensing promotes radiation-induced type I interferon-dependent antitumor immunity in immunogenic tumors","volume":"41","author":"Deng","year":"2014","journal-title":"Immunity"},{"key":"B76","doi-asserted-by":"publisher","first-page":"42","DOI":"10.1007\/s11060-025-05299-0","article-title":"Clinical predictors of pseudoprogression in glioblastoma: a retrospective cohort analysis","volume":"176","author":"Hoosemans","year":"2025","journal-title":"J Neuro-Oncol"},{"key":"B77","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2025.1714287","article-title":"Cerebrospinal fluid ctDNA as a diagnostic and prognostic tool in gliomas: a systematic review and meta-analysis","volume":"15","author":"Perez-Alfayate","year":"2025","journal-title":"Front Oncol"},{"key":"B78","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2025.1731258","article-title":"Explainable, modality-adaptive radiomics for MGMT methylation prediction in high-grade glioma: a decision-curve analysis study","volume":"15","author":"Christodoulou","year":"2026","journal-title":"Front Oncol"},{"key":"B79","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejrai.2026.100074","article-title":"Explainable radiomics with probability calibration for postoperative glioblastoma surveillance","volume":"5","author":"Christodoulou","year":"2026","journal-title":"Eur J Radiol Artif Intell"},{"key":"B80","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2026.1812518","article-title":"Multimodal artificial intelligence in glioma management: integrating neuroimaging and hematologic biomarkers for precision oncology","volume":"16","author":"Christodoulou","year":"2026","journal-title":"Front Oncol"},{"key":"B81","article-title":"Intratumoral 224Ra-loaded wires spread alpha-emitters inside solid human tumors in athymic mice achieving tumor control","volume":"32","author":"Cooks","year":"2012","journal-title":"Anticancer Res"},{"key":"B82","article-title":"Feasibility and safety of diffusing alpha-emitter radiation therapy for recurrent or unresectable skin cancers","volume":"6","author":"D'Andrea","year":"2023","journal-title":"JAMA Netw Open"},{"key":"B83","doi-asserted-by":"publisher","DOI":"10.1097\/cco.0000000000000990","article-title":"Unveiling the enigma of the blood-brain barrier in glioblastoma: current advances from preclinical and clinical studies","volume":"35","author":"Ahmed","year":"2023","journal-title":"Curr Opin Oncol"},{"key":"B84","doi-asserted-by":"publisher","first-page":"035016","DOI":"10.1088\/1361-6560\/abd3ef","article-title":"Effect of microdistribution of alpha and beta-emitters in targeted radionuclide therapies on delivered absorbed dose in a GATE model of bone marrow","volume":"66","author":"Tranel","year":"2021","journal-title":"Phys Med Biol"},{"key":"B85","doi-asserted-by":"publisher","DOI":"10.3390\/pharmaceutics16111458","article-title":"Optimization processes of clinical chelation-based radiopharmaceuticals for pathway-directed targeted radionuclide therapy in oncology","volume":"16","author":"Tomiyoshi","year":"2024","journal-title":"Pharmaceutics"}],"container-title":["Frontiers in Oncology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2026.1940181\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,4]],"date-time":"2026-09-04T13:51:28Z","timestamp":1788529888000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2026.1940181\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,4]]},"references-count":85,"alternative-id":["10.3389\/fonc.2026.1940181"],"URL":"https:\/\/doi.org\/10.3389\/fonc.2026.1940181","relation":{},"ISSN":["2234-943X"],"issn-type":[{"value":"2234-943X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9,4]]},"article-number":"1940181"}}